Income Tax Expense
The latest quarterly tax expense is $21.90 Million with a quarter-over-quarter change of -43.12%. Income tax expense is the amount a company pays in federal, state, and foreign income taxes based on its taxable income for the period.
PODD Tax Expense
Reported quarterly tax expense; no daily interpolation.
Current Tax Expense
$21.90M
$21.90 Million
Quarter-over-Quarter Change
-43.12%
vs. $38.50M prior quarter
Historical Data
85
Quarters of data available
Quarterly Tax Expense History
| Period | Tax Expense | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $21.90M | $-16.60M | -43.12% |
| Q4 2025 | $38.50M | +$3.30M | +9.38% |
| Q3 2025 | $35.20M | +$29.30M | +496.61% |
| Q2 2025 | $5.90M | $-6.80M | -53.54% |
| Q1 2025 | $12.70M | +$2.10M | +19.81% |
| Q4 2024 | $10.60M | +$5.20M | +96.30% |
| Q3 2024 | $5.40M | +$142.90M | +103.93% |
| Q2 2024 | $-137.50M | $-140.90M | -4144.12% |
| Q1 2024 | $3.40M | $-1.10M | -24.44% |
| Q4 2023 | $4.50M | +$2.70M | +150.00% |
| Q3 2023 | $1.80M | +$600,000 | +50.00% |
| Q2 2023 | $1.20M | +$400,000 | +50.00% |
| Q1 2023 | $800,000 | $-4.50M | -84.91% |
| Q4 2022 | $5.30M | +$5.80M | +1160.00% |
| Q3 2022 | $-500,000 | +$600,000 | +54.55% |
| Q2 2022 | $-1.10M | $-2.60M | -173.33% |
| Q1 2022 | $1.50M | $-2.70M | -64.29% |
| Q4 2021 | $4.20M | +$1.60M | +61.54% |
| Q3 2021 | $2.60M | +$6.00M | +176.47% |
| Q2 2021 | $-3.40M | $-3.10M | -1033.33% |
| Q1 2021 | $-300,000 | +$1.10M | +78.57% |
| Q4 2020 | $-1.40M | $-3.20M | -177.78% |
| Q3 2020 | $1.80M | $-1.20M | -40.00% |
| Q2 2020 | $3.00M | +$3.50M | +700.00% |
| Q1 2020 | $-500,000 | $-2.31M | -127.56% |
| Q4 2019 | $1.81M | +$1.51M | +504.67% |
| Q3 2019 | $300,000 | $-200,000 | -40.00% |
| Q2 2019 | $500,000 | +$200,000 | +66.67% |
| Q1 2019 | $300,000 | $-695,000 | -69.85% |
| Q4 2018 | $995,000 | +$801,000 | +412.89% |
| Q3 2018 | $194,000 | $-218,000 | -52.91% |
| Q2 2018 | $412,000 | +$79,000 | +23.72% |
| Q1 2018 | $333,000 | +$394,000 | +645.90% |
| Q4 2017 | $-61,000 | $-182,000 | -150.41% |
| Q3 2017 | $121,000 | +$20,000 | +19.80% |
| Q2 2017 | $101,000 | +$5,000 | +5.21% |
| Q1 2017 | $96,000 | $-101,000 | -51.27% |
| Q4 2016 | $197,000 | +$131,000 | +198.48% |
| Q3 2016 | $66,000 | +$1,000 | +1.54% |
| Q2 2016 | $65,000 | +$1,000 | +1.56% |
| Q1 2016 | $64,000 | $-76,000 | -54.29% |
| Q4 2015 | $140,000 | +$96,000 | +218.18% |
| Q3 2015 | $44,000 | +$29,000 | +193.33% |
| Q2 2015 | $15,000 | $-9,000 | -37.50% |
| Q1 2015 | $24,000 | +$20,000 | +500.00% |
| Q4 2014 | $4,000 | $-17,000 | -80.95% |
| Q3 2014 | $21,000 | $-31,000 | -59.62% |
| Q2 2014 | $52,000 | $-13,000 | -20.00% |
| Q1 2014 | $65,000 | +$219,000 | +142.21% |
| Q4 2013 | $-154,000 | $-159,000 | -3180.00% |
| Q3 2013 | $5,000 | $-113,000 | -95.76% |
| Q2 2013 | $118,000 | $-13,000 | -9.92% |
| Q1 2013 | $131,000 | +$62,000 | +89.86% |
| Q4 2012 | $69,000 | +$41,000 | +146.43% |
| Q3 2012 | $28,000 | $-41,000 | -59.42% |
| Q2 2012 | $69,000 | +$23,000 | +50.00% |
| Q1 2012 | $46,000 | +$46,000 | — |
| Q4 2011 | $0 | +$0 | — |
| Q3 2011 | $0 | +$11.34M | +100.00% |
| Q2 2011 | $-11.34M | $-11.34M | — |
| Q1 2011 | $0 | +$0 | — |
| Q4 2010 | $0 | +$0 | — |
| Q3 2010 | $0 | +$0 | — |
| Q2 2010 | $0 | +$0 | — |
| Q1 2010 | $0 | +$0 | — |
| Q4 2009 | $0 | +$0 | — |
| Q3 2009 | $0 | +$0 | — |
| Q2 2009 | $0 | +$0 | — |
| Q1 2009 | $0 | +$0 | — |
| Q4 2008 | $0 | +$0 | — |
| Q3 2008 | $0 | +$0 | — |
| Q2 2008 | $0 | +$0 | — |
| Q1 2008 | $0 | +$0 | — |
| Q4 2007 | $0 | +$0 | — |
| Q3 2007 | $0 | +$0 | — |
| Q2 2007 | $0 | +$0 | — |
| Q1 2007 | $0 | +$0 | — |
| Q4 2006 | $0 | +$0 | — |
| Q3 2006 | $0 | +$0 | — |
| Q2 2006 | $0 | +$0 | — |
| Q1 2006 | $0 | +$0 | — |
| Q4 2005 | $0 | +$0 | — |
| Q3 2005 | $0 | +$0 | — |
| Q2 2005 | $0 | +$0 | — |
| Q1 2005 | $0 | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy